AU2014212109B2 - Compositions and methods for the treatment of neurodegenerative and other diseases - Google Patents

Compositions and methods for the treatment of neurodegenerative and other diseases Download PDF

Info

Publication number
AU2014212109B2
AU2014212109B2 AU2014212109A AU2014212109A AU2014212109B2 AU 2014212109 B2 AU2014212109 B2 AU 2014212109B2 AU 2014212109 A AU2014212109 A AU 2014212109A AU 2014212109 A AU2014212109 A AU 2014212109A AU 2014212109 B2 AU2014212109 B2 AU 2014212109B2
Authority
AU
Australia
Prior art keywords
sulfasalazine
pharmaceutical composition
patient
pvp
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014212109A
Other languages
English (en)
Other versions
AU2014212109A1 (en
Inventor
Douglas Alan Lorenz
David Keith Lyon
Mark Wade Moore
Thaddeus Cromwell Reeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glialogix Inc
Original Assignee
Glialogix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glialogix Inc filed Critical Glialogix Inc
Publication of AU2014212109A1 publication Critical patent/AU2014212109A1/en
Application granted granted Critical
Publication of AU2014212109B2 publication Critical patent/AU2014212109B2/en
Priority to AU2018222921A priority Critical patent/AU2018222921A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014212109A 2013-02-01 2014-01-31 Compositions and methods for the treatment of neurodegenerative and other diseases Ceased AU2014212109B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018222921A AU2018222921A1 (en) 2013-02-01 2018-08-28 Compositions and methods for the treatment of neurodegenerative and other diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361759933P 2013-02-01 2013-02-01
US61/759,933 2013-02-01
US201361780340P 2013-03-13 2013-03-13
US61/780,340 2013-03-13
PCT/US2014/014290 WO2014121137A2 (en) 2013-02-01 2014-01-31 Compositions and methods for the treatment of neurodegenerative and other diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018222921A Division AU2018222921A1 (en) 2013-02-01 2018-08-28 Compositions and methods for the treatment of neurodegenerative and other diseases

Publications (2)

Publication Number Publication Date
AU2014212109A1 AU2014212109A1 (en) 2015-08-06
AU2014212109B2 true AU2014212109B2 (en) 2018-05-31

Family

ID=50382538

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014212109A Ceased AU2014212109B2 (en) 2013-02-01 2014-01-31 Compositions and methods for the treatment of neurodegenerative and other diseases
AU2018222921A Abandoned AU2018222921A1 (en) 2013-02-01 2018-08-28 Compositions and methods for the treatment of neurodegenerative and other diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018222921A Abandoned AU2018222921A1 (en) 2013-02-01 2018-08-28 Compositions and methods for the treatment of neurodegenerative and other diseases

Country Status (10)

Country Link
US (5) US9597339B2 (cg-RX-API-DMAC10.html)
EP (1) EP2950797B1 (cg-RX-API-DMAC10.html)
JP (2) JP6328146B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150139830A (cg-RX-API-DMAC10.html)
CN (1) CN105163735B (cg-RX-API-DMAC10.html)
AU (2) AU2014212109B2 (cg-RX-API-DMAC10.html)
CA (1) CA2899032A1 (cg-RX-API-DMAC10.html)
ES (1) ES2752021T3 (cg-RX-API-DMAC10.html)
IL (1) IL240206A0 (cg-RX-API-DMAC10.html)
WO (1) WO2014121137A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597339B2 (en) * 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
KR102364840B1 (ko) 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
US20160199393A1 (en) * 2015-01-08 2016-07-14 China Medical University Methods of treating brain ischemia or hypoxia
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
EP3448431A4 (en) * 2016-04-26 2020-01-01 Saint Louis University HIGHLY SELECTIVE ADENOSINE A3 RECEPTOR SUBTYPAGONSISTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
US10473672B2 (en) * 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
RU2680844C1 (ru) * 2017-10-12 2019-02-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Применение сульфасалазина в качестве ингибитора образования конечных продуктов гликирования
JP6603815B2 (ja) * 2017-11-21 2019-11-06 積水化学工業株式会社 皮膚外用剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072308A1 (en) * 2000-03-28 2001-10-04 Neurotech Co., Ltd. Composition and method for intervening neuronal death using sulfasalazine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
RU2147226C1 (ru) 1994-09-29 2000-04-10 Квадрант Хэлткэа (Ю Кей) Лимитед Высушенные распылением микрочастицы как терапевтические носители
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ITMI962356A1 (it) 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
CA2341624C (en) 1998-08-25 2008-12-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CA2307278A1 (en) 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1824564A4 (en) 2004-10-27 2009-09-16 Uab Research Foundation METHOD FOR TREATING GLIOM
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
US20070053869A1 (en) 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
KR20140016439A (ko) 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
US7964585B2 (en) 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
NZ575171A (en) 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2259777A2 (en) * 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
EP2113254B1 (en) * 2008-04-28 2012-08-15 TXCell Compositions for treating an inflammatory auto-immune condition
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
EP2811980A4 (en) 2012-01-31 2015-12-23 Cerulean Pharma Inc POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF
US9597339B2 (en) * 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
CN113209024A (zh) 2013-12-31 2021-08-06 阿森迪亚制药有限责任公司 疏水性化合物的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072308A1 (en) * 2000-03-28 2001-10-04 Neurotech Co., Ltd. Composition and method for intervening neuronal death using sulfasalazine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Asija Rajesh ET AL, "EFFECT OF THE PREPARATION OF SOLID DISPERSION METHOD ON THE SOLUBILITY AND CRYSTALLINITY OF SULFASALAZINE", International Research Journal of Pharmacy (2011), pages 200-206, URL:http://irjponline.com/vol2/issue4/38.pdf *
Asija Rajesh ET AL, "INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ENHANCED SOLUBILITY STUDY OF SULPHASALAZINE USING DIFFERENT SOLUBILIZATION TECHNIQUES", (2012-01-01), URL: http://www.irjponline.com/admin/php/uploads/1312_pdf.pdf *
B. R. RYU, "The Novel Neuroprotective Action of Sulfasalazine through Blockade of NMDA Receptors", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2003-01-21), vol. 305, no. 1, doi:10.1124/jpet.102.042606, pages 48 - 56 *

Also Published As

Publication number Publication date
US20170079990A1 (en) 2017-03-23
CN105163735A (zh) 2015-12-16
US20170165279A1 (en) 2017-06-15
AU2014212109A1 (en) 2015-08-06
WO2014121137A2 (en) 2014-08-07
ES2752021T3 (es) 2020-04-02
EP2950797A2 (en) 2015-12-09
IL240206A0 (en) 2015-09-24
CA2899032A1 (en) 2014-08-07
EP2950797B1 (en) 2019-09-11
US20170079991A1 (en) 2017-03-23
WO2014121137A3 (en) 2014-11-27
JP2016507526A (ja) 2016-03-10
AU2018222921A1 (en) 2018-09-20
US10398713B2 (en) 2019-09-03
US9918997B2 (en) 2018-03-20
US20140221321A1 (en) 2014-08-07
US9974798B2 (en) 2018-05-22
JP6328146B2 (ja) 2018-05-23
JP2018123159A (ja) 2018-08-09
US20190015431A1 (en) 2019-01-17
KR20150139830A (ko) 2015-12-14
US9980978B2 (en) 2018-05-29
CN105163735B (zh) 2018-12-11
US9597339B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
US10398713B2 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
JP7397239B2 (ja) インターロイキン－２３受容体のペプチド阻害剤の組成物
Panakanti et al. Impact of excipient interactions on drug bioavailability from solid dosage forms
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
JP2023513249A (ja) オメカムチブメカルビル製剤
CN101795673A (zh) 增强的拉莫三嗪制剂
US20200009118A1 (en) Compositions and methods for the treatmentof neurodegenerative and other diseases
JP5048492B2 (ja) 活性成分を含有する胃貯留錠の形態の薬学的組成物
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
US20240100011A1 (en) Pediatric formulations of ferric citrate
CN107205947B (zh) 用于治疗胃肠道疾病的药物组合物
TW200811123A (en) Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
RU2773029C2 (ru) Галеновые композиции органических соединений
HK40092077A (en) Compositions of peptide inhibitors of interleukin-23 receptor
US20170340573A1 (en) Raloxifene sprinkle composition
HK1250932A1 (en) Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
BR112017022509A2 (en) diacerein-containing formulations and methods for lowering blood levels of uric acid using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired